“Resistance to Pembrolizumab and Axitinib in Renal Cell Carcinoma: Clinical and Genomic Evaluation” (2020) Journal of Kidney Cancer, 7(1), pp. 7–11. doi:10.15586/jkcvhl.2020.135.